2C-B-FLY-NBOMe Stats & Data

• Identity/testing: Because NBOMes are frequently sold on blotter as “acid,” always test. LSD gives a purple positive on Ehrlich reagent and typically fluoresces under UV; NBOMes do not fluoresce and have distinct reagent patterns. Marquis/Mecke are unreliable for confirming LSD but can flag NBOMe-like reactions; reagent testing cannot prove identity, only rule-in/out patterns. Use multiple reagents and, where possible, lab drug-checking.

• Oral activity nuance: NBOMes were long thought orally inactive when swallowed, but some salts show measurable oral bioavailability. Do not assume a swallowed NBOMe blotter is inactive; discard blotter after buccal/sublingual application rather than swallowing if avoiding further exposure.

• Microgram potency & volumetric dosing: Overdoses often stem from mismeasurement/static loss. Volumetric dosing substantially reduces risk: dissolve a precisely weighed amount into an appropriate solvent (e.g., high-proof ethanol or propylene glycol for poor water solubility), clearly label concentration, and measure volume for dosing.

• Route risk: Intranasal use is linked to a disproportionate number of severe cases (agitation, hyperthermia, seizures, ischemia). If used intranasally, reduce dose substantially versus buccal/sublingual and avoid co-stimulants.

• Vasoconstriction & heat risk: NBOMes can cause marked peripheral vasoconstriction (cold/numb digits, pallor/cyanosis) and hyperthermia/rhabdomyolysis at high doses. Keep ambient temperature moderate, avoid overexertion, and hydrate with electrolytes. Urgent care is indicated for chest pain, extreme agitation, limb discoloration/numbness, confusion, seizures, or hot/dry skin and altered consciousness.

• Combination risks: Avoid serotonergic combinations (e.g., MDMA, DXM) due to serotonin toxicity; avoid stimulants (cocaine/amphetamines) due to compounding vasoconstriction/arrhythmia risk; avoid tramadol due to seizures. Cannabis and dissociatives can unpredictably potentiate effects—go slowly or avoid.

• Acute management (for bystanders/clinicians): Calm, cooling, fluids and benzodiazepines are commonly used for severe agitation; antipsychotics may be used by professionals for frank psychosis but are not first-line for simple panic. Seek medical help early for hyperthermia or severe hypertension. Do not self-medicate with additional substances during a crisis.

• Mislabeling: EU and US monitoring documented NBOMes sold as LSD or 2C drugs on blotter and as powders; treat unknown “LSD-like” blotter with caution.

• Metabolism: Across NBOMe analogs studied in human liver microsomes and animals, major pathways include O-demethylation and N-debenzylation; inter-individual variability is likely. This may prolong or intensify effects in some users; titrate cautiously and avoid redosing in the same session.

• Solubility/handling: Freebase NBOMes are poorly water-soluble; solutions in high-proof ethanol or mixed PEG-400/ethanol are used by some to prepare 50–500 µg/mL standards. Label and store away from light/heat; prevent skin/mucosa exposure when handling powders or solutions.

• Tolerance/spacing: Response varies between sessions; a steep dose-response and rapid tolerance mean that redosing often adds side effects more than benefits. Space sessions by 2–3+ weeks to reduce tachyphylaxis and psychological after-load.